STOCK TITAN

Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) to Present at 43rd Annual Canaccord Genuity Growth Conference
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Tenaya senior management will participate in the 43rd Annual Canaccord Genuity Growth Conference taking place in Boston. Details of participation are as follows:

Tenaya Therapeutics Company Presentation 
Date: August 9, 2023
Time: 8:00 AM PT / 11:00 AM ET

A webcast of the presentation will be available for approximately 90 days by visiting the Investors section of Tenaya’s website.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com.

Contacts

Investors
Michelle Corral
Vice President, Investor Relations and Corporate Communications
Tenaya Therapeutics
IR@tenayathera.com

Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com


FAQ

What is the upcoming event for Tenaya Therapeutics, Inc. (NASDAQ: TNYA)?

Tenaya senior management will participate in the 43rd Annual Canaccord Genuity Growth Conference in Boston.

When will the presentation take place?

The presentation is scheduled for August 9, 2023, at 8:00 AM PT / 11:00 AM ET.

Where can I watch the webcast of the presentation?

The webcast will be available for approximately 90 days on the Investors section of Tenaya’s website.

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

TNYA Rankings

TNYA Latest News

TNYA Stock Data

333.70M
42.73M
1.53%
77.18%
3.93%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO

About TNYA

tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.